March 6, 2018
Authored and Edited by Ashley M. Winkler; Susan Y. Tull
On March 2, 2018, FDA issued draft guidance on the definitions of “suspect product” and “illegitimate product” for verification obligations under the Drug Supply Chain Security Act (DSCSA). FDA intends the new draft guidance to assist trading partners in meeting the verification obligations of the DSCSA.
The DSCSA, which was enacted on November 27, 2013, established requirements for product tracing, verification, and product identification for certain drug products sold in the US. More particularly, the verification obligations of the DSCSA require trading partners to identify a suspect product and make a determination about whether that product is an illegitimate product.
FDA clarifies its interpretation of the following four terms used in the definitions of “suspect product” and “illegitimate product”: (1) counterfeit, (2) diverted, (3) fraudulent transaction, and (4) unfit for distribution. While not exhaustive, in this guidance, FDA identifies the most common scenarios that FDA believes trading partners will encounter with respect to these terms.
Readers are encouraged to read the draft guidance, also available on FDA’s website. Comments and suggestions regarding the draft guidance should be submitted to FDA by May 1, 2018.
Food and Drug Administration (FDA), FDA Guidance, drugs, Biologic License Application (BLA), new drug application (NDA)
Copyright © 2018 Finnegan, Henderson, Farabow, Garrett & Dunner, LLP.
DISCLAIMER: Although we wish to hear from you, information exchanged in this blog cannot and does not create an attorney-client relationship. Please do not post any information that you consider to be personal or confidential. If you wish for Finnegan, Henderson, Farabow, Garrett & Dunner, LLP to consider representing you, in order to establish an attorney-client relationship you must first enter a written representation agreement with Finnegan. Contact us for additional information. One of our lawyers will be happy to discuss the possibility of representation with you. Additional disclaimer information.
Lecture
Patent Protection for Software-Related Inventions in Europe and the USA Training Course
June 5, 2024
Hybrid
Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.
We use cookies on this website to provide you with the best user experience. By accepting cookies, you agree to our use of cookies. Please note that if you opt not to accept or if you disable cookies, the “Your Finnegan” feature on this website will be disabled as well. For more information on how we use cookies, please see our Privacy Policy.
Finnegan is thrilled to announce the launch of our new blog, Ad Law Buzz, devoted solely to breaking news, developments, trends, and analysis in advertising law.